A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)

NCT06516952 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

330

Enrollment

INDUSTRY

Sponsor class

Conditions

Prurigo Nodularis

Interventions

DRUG: Povorcitinib
DRUG: Placebo

Sponsor

Incyte Corporation